Phase 2 trial demonstrates significant reduction of S. aureus colonization with probiotic use

A new NIH study sheds light on the gut’s role in colonizing staph. In a Phase 2 clinical study, a promising method to control Staphylococcus Aureus bacteria colonization was found to be safe and highly efficient. The Lancet Microbe reported that the new study found that Bacillus subtilis, a probiotic, significantly reduced S. The probiotic Bacillus subtilis reduced S. […]

First patient enrolled in the U.S. Arise Study for the treatment of knee osteoarthritis, announced by LIPOGEMS

Lipogems announced that the first patient would be enrolled into the ARISE U.S. FDA IDE Study by January 13, 2023. The study compares MicroFat injections with steroid ones for treating Knee Osteoarthritis. It’s a great time! “We screened this patient on December 30, 2022, and I’m proud to have enrolled the first patient,” stated Dr. YogeshMittal. He […]

Southern California’s Hoag initiates Phase I Clinical Trial, becoming the first to treat Recurrent Neuroendocrine Cancers

A new alpha radiation treatment could revolutionize cancer treatment. Hoag Memorial Hospital Presbyterian became the first hospital to offer a clinical trial in Southern California, and is one of the few hospitals in the entire world to do so. This clinical trial could change the way cancer treatments are delivered. Hoag has launched a phase […]

Study reveals that annual or biannual boosters are most effective in combating endemic COVID-19

COVID-19 boosters are effective in protecting against hospitalization and severe illness. However, their effectiveness is waning, leading to confusion about the best time to receive an additional booster. A team of scientists, led by professors at the Yale School of Public Health at Charlotte and the University of North Carolina at Charlotte, has the answer: […]

Breakthrough Device Designation granted to Medcura for its LifeGelâ„¢ Absorbable Surgical Hemostat

Medcura, Inc., an innovative medical device company committed to improving surgical bleeding management, announced that the U.S. Food and Drug Administration has awarded the Breakthrough Device Designation to its LifeGel ™ Absorbable Hemostat. LifeGel ™ was the first hemostatic agent to be granted Breakthrough Device Designation. It is intended for a highly differentiated and new indication […]

Successful completion of toxicity study for CAN10 antibody by Cantargia paves the way for phase I clinical trial application

Cantargia AB (Nasdaq Stockholm CANTA) has announced the conclusion of its Good Laboratory Practices (GLP) toxicity studies for CAN10, an anti-inflammatory IL1RAP binding antibody. The study showed that CAN10 is well tolerated if administered for six weeks. Cantargia intends to begin the phase I clinical trials for CAN10 in the first half 2023. In the current GLP […]

Groundbreaking decentralized study reveals significant user engagement with Huma’s study app

Huma Therapeutics Limited (Huma), a leading digital health company in the world, has announced the results of an innovative study conducted in collaboration with Medical Research Council Epidemiology Unit, University of Cambridge. The study showed that participants who used Huma’s platform for clinical trials had sustained high levels of engagement during a fully remote observational […]